Enoxaparin

Overview

Enoxaparin is a low molecular weight heparin (LMWH) used in veterinary medicine as an anticoagulant for the prevention and treatment of thromboembolic disease in dogs and cats. It is administered subcutaneously and is characterized by more predictable anticoagulant effects compared with unfractionated heparin.

Following subcutaneous administration, enoxaparin is rapidly absorbed and provides anticoagulant activity primarily through inhibition of factor Xa. In animals, its duration of effect may be shorter than in humans, often requiring more frequent dosing to maintain therapeutic activity.

Mechanism of Action (MOA): Enoxaparin binds to and enhances the activity of antithrombin, leading to inhibition of factor Xa and, to a lesser extent, thrombin. Compared with unfractionated heparin, it preferentially inhibits factor Xa and has minimal effects on routine clotting times.

Indications

Enoxaparin is used in dogs and cats primarily for the prevention and treatment of thromboembolic disorders. Its use in veterinary medicine is based on limited clinical data, and dosing strategies are often extrapolated from pharmacokinetic studies and human medicine.

• Thromboembolic disease (treatment and prophylaxis): Used to prevent or manage thrombus formation in conditions associated with hypercoagulability.
• Immune-mediated hemolytic anemia (IMHA): Commonly used in dogs as part of a multimodal protocol to reduce the risk of thromboembolic complications.
• High-risk thrombotic conditions: May be considered in patients with diseases or clinical states that predispose to thrombosis, although evidence in veterinary patients remains limited.

Dosage (Reference)

Dog

In dogs, enoxaparin is administered subcutaneously for thromboprophylaxis. Due to variability in pharmacokinetics and limited clinical data, dosing is not well established and should be individualized based on response and monitoring.

Cat

In cats, enoxaparin is used subcutaneously for thromboprophylaxis. Due to a shorter duration of factor Xa inhibition, more frequent dosing may be required to maintain consistent anticoagulant activity.

Warnings & Precautions

Enoxaparin is an anticoagulant that requires careful use in patients at risk of bleeding or with conditions affecting drug metabolism and clearance. Appropriate patient selection and monitoring are essential to minimize complications.

• Active bleeding disorders: Contraindicated in patients with active major hemorrhage or conditions associated with significant bleeding risk.
• Heparin-induced thrombocytopenia (HIT): Contraindicated in patients with a history of HIT or hypersensitivity to heparin or low molecular weight heparins.
• Hypersensitivity: Avoid use in patients with known hypersensitivity to enoxaparin, heparin, LMWHs, or porcine-derived products.
• Risk of hemorrhage: Use with extreme caution in patients with congenital or acquired bleeding disorders or those at increased risk of bleeding.
• Epidural or spinal procedures: Increased risk of bleeding complications; use with extreme caution in patients receiving epidural anesthesia.
• Renal and hepatic impairment: Use cautiously as drug accumulation may occur, increasing the risk of bleeding.
• Uncontrolled hypertension and vascular disease: Increased risk of hemorrhage; caution advised in patients with severe hypertension, recent GI ulceration, or diabetic retinopathy.
• Route of administration: Must be given subcutaneously only; do not administer intramuscularly or intravenously.
• Product interchangeability: Not interchangeable with other low molecular weight heparins or unfractionated heparin due to differences in dosing and activity.

Drug Interactions

Drug interactions with enoxaparin are primarily related to an increased risk of hemorrhage when combined with other agents that affect coagulation or platelet function.

• Oral anticoagulants (e.g. warfarin): Increased risk of hemorrhage with concurrent use.
• NSAIDs (e.g. carprofen, meloxicam, robenacoxib): Increased risk of bleeding due to effects on platelet function and GI mucosa.
• Platelet aggregation inhibitors (e.g. aspirin, clopidogrel): Additive anticoagulant effects increase risk of hemorrhage.
• Selective serotonin reuptake inhibitors (SSRIs; e.g. fluoxetine, sertraline): May increase bleeding risk through effects on platelet function.
• Thrombolytic agents: Markedly increased risk of hemorrhage when used concurrently.

Side Effects & Overdose

Side Effects

Adverse effects of enoxaparin are generally uncommon but are primarily related to bleeding risk and local injection site reactions.

• Hemorrhage: Uncommon but possible; reported in a proportion of treated animals.
• Injection site reactions: Pain, bruising (ecchymosis), erythema, and hematoma may occur.
• Hematologic effects: Anemia and thrombocytopenia have been reported.
• Systemic effects: Nausea and fever may occur (reported in human data).

Overdose

Overdose of enoxaparin primarily results in excessive anticoagulation and an increased risk of hemorrhagic complications.

• Hemorrhage: Primary clinical concern in overdose.
• Management: Protamine sulfate may be administered as an antidote.
• Protamine dosing: 1 mg IV (slow) per 1 mg enoxaparin given within the previous 8 hours.
• Delayed or repeat dosing: If more than 8 hours have passed or additional reversal is needed, 0.5 mg protamine per 1 mg enoxaparin may be given slowly IV.
• Caution: Avoid overdosing protamine sulfate.

Key Notes

Practical clinical points that help optimize the use of enoxaparin in veterinary patients:

• Limited veterinary evidence: Clinical use in dogs and cats is based on limited studies, and overall efficacy and cost-effectiveness remain uncertain.
• Breed variability (dogs): Pharmacodynamic response may differ between breeds, meaning similar doses may not produce consistent anticoagulant effects.
• Anti-Xa monitoring limitations: Anti-factor Xa activity does not always correlate with true antithrombotic effect, particularly in cats.
• Shorter duration in animals: Compared to humans, duration of activity may be shorter in dogs and cats, influencing dosing frequency decisions.
• Pharmacokinetic–pharmacodynamic mismatch: Measured drug levels may not fully reflect clinical anticoagulant effect in vivo.
• Economic considerations: Cost may limit long-term or intensive use, especially when frequent dosing is required.